Plavix

High Doses Of Plavix May Be Good For Some Patients, But Not All.

Tuesday, September 14th, 2010

Source: DIA Daily HealthDay (9/1, Reinberg) reported that “more isn’t necessarily better when prescribing the two drugs commonly used to treat patients who are in danger of having a heart attack, Plavix (clopidogrel) and aspirin,” according to a study. Two separate “reports on the data,” one published online in The Lancet and the other published […]

Reduced Plavix Efficacy Associated With Specific Gene Variants Confirmed In Two New Analyses, But Not In A Third.

Monday, August 30th, 2010

Source: DIA Daily The Wall Street Journal (8/30, Winslow) reports that for patients with acute coronary syndrome, physicians often turn to Sanofi-Aventis and Bristol-Myers Squibb’s Plavix (clopidogrel) to prevent clot-induced strokes and heart attacks. However, a significant number of patients carry genetic variations that impede the drug’s effectiveness. While some believe a genetic test could […]

Early dual antiplatelet therapy cuts microemboli risk after cerebral stenosis

Wednesday, May 5th, 2010

Source: MedWire News Early combination antiplatelet therapy results in fewer microemboli relative to aspirin monotherapy in patients with symptomatic cerebral or carotid artery stenosis, show results of the CLAIR study. “Clinical trials are now warranted to investigate whether this combination treatment also results in a reduction in stroke incidence,” write the CLAIR (Clopidogrel plus aspirin […]

Plavix May Reduce Death Risk In Patients With Certain Heart Conditions.

Wednesday, March 24th, 2010

HealthDay (3/22, Preidt) reported that “Plavix [clopidogrel] is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don’t undergo angioplasty,” according to a study published in the Journal of the American College of Cardiology. In the study, “there were 812 deaths (32.2 percent) among heart failure […]

New anti-clotting drug performs better than Plavix in study.

Thursday, January 14th, 2010

Source: DIA Daily MedPage Today (1/13, Peck) reported that, “among patients who underwent planned stenting for treatment of acute coronary syndromes, those treated with the investigational antiplatelet agent ticagrelor (Brilinta) had fewer cardiovascular events than patients who received clopidogrel (Plavix).” This “finding emerged from a prespecified subset analysis of the PLATO (Study of Platelet Inhibition […]

PPIs and Plavix — Confusion Reigns Supreme

Wednesday, November 18th, 2009

By Burt Cohen Patients taking Plavix (a.k.a. clopidogrel) — and that would be all stent patients — sometimes experience a side effect of gastric upset, heartburn or even bleeding. So they are given a Proton Pump Inhibitor (PPI) with a brand name of Prilosec, Nexium, Prevacid or Protonix to alleviate these symptoms. In the past a […]

Double dose of Plavix better for certain angioplasty patients

Tuesday, September 29th, 2009

HealthDay (9/28, Edelson) reported that “cardiologists are looking at the next generation of clot-busters that could replace Plavix [clopidogrel].” In a study “published in the Oct. 6 issue of the Journal of the American College of Cardiology,” researchers “found that a 600-milligram dose of Plavix is more effective than a 300-milligram dose during angioplasty for […]

Research suggests adding Plavix to aspirin may reduce heart risks in atrial fibrillation patients.

Wednesday, April 1st, 2009

 The Wall Street Journal (4/1, D5, Loftus) reports that “adding the anticlotting drug Plavix [clopidogrel] to aspirin in people with” atrial fibrillation “modestly reduced the combined risk of strokes and related disease versus aspirin alone,” according to a study presented at the American College of Cardiology conference and published online in the New England Journal […]

US FDA seeks more data on bloodthinner PlavixUS FDA seeks more data on bloodthinner Plavix

Tuesday, January 27th, 2009

US FDA seeks more data on bloodthinner Plavix U.S. health regulators are reviewing the effectiveness in some patients of the widely used blood thinner Plavix, made by Sanofi-Aventis SA and Bristol-Myers Squibb Co. The move comes after several studies found the blockbuster drug did not work as well in certain people possibly because patients metabolized it […]

Study suggests 11 percent of patients discontinue clopidogrel due to nuisance bleeding.

Tuesday, December 30th, 2008

Study suggests 11 percent of patients discontinue clopidogrel due to “nuisance bleeding.” Medscape /HeartWire (12/29, O’Riordan) reported that, according to a study published Dec. 10 in the American Journal of Cardiology, patients may experience “‘nuisance bleeding’ on clopidogrel (Plavix) …therapy following stent implantation,” and, as a result, “more than one in 10 of patients stops […]